Search


Jefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects
He discusses the regulatory status of Lyme disease, which hit on secondary endpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella. Coverage brought to you by
3 days ago


BIO-Europe 2025: Valneva's partner Pfizer has been running a key trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine license. Coverage brought to you by:
Nov 3, 2025






.png)
